

Re: Your request made under the Freedom of Information Act 2000

Q1. Does your trust treat myelofibrosis? If not, which other trust do you refer these patients to?

YES

Q2.

A) Please provide the total number of patients treated in the last 6 months (or the latest 6 months data you have available) for myelofibrosis (ICD10 code D47.4).

110

b) How many of these patients were above age 65?

18

Q3. How many myelofibrosis patients were treated in the past 6 months with Ruxolitinib?

Q4.

A) How many myelofibrosis (ICD10 code D47.4) patients has your trust diagnosed in the past 3 years?

b) Of these patients, how many were treated in the past 6 months (or the latest 6 months data you have available) with:

- Hydroxyurea
- Fedratinib
- Received No Treatment
- We cannot answer question 3 and 4 as **Our pharmacy system doesn't store diagnosis data, so we're unable to determine this against the prescribed treatment. To ascertain this data,**

Our Ref: 136/2022

JANUARY 2022

the Trust would need to perform an audit of each individual patient record, which wouldn't be achievable within the s.12 timescale of the Freedom of Information Act 2000.

Q5. Does your trust participate in any clinical trials for the treatment of myelofibrosis? If so, can you please provide the name of each trial along with the number of patients taking part.

NO TRIALS RUNNING